Possibilities of using alternative schemes of sunitinib therapy in patients with metastatic renal cell carcinoma
https://doi.org/10.18027/2224-5057-2017-2-90-93
Abstract
Sunitinib is one of the main drugs for the first line therapy for clear cell metastatic renal cell carcinoma (mRCC). At present, in order to achieve the optimal level of concentration of the drug in the plasma, the standard therapy regimen is 4/2 – 4 weeks of daily intake of 50 mg of sunitinib followed by a break for 2 weeks. However, with this scheme, side effects are often encountered. It makes necessary to reduce the dosage of the drug. Over the past few years, there is a growing evidence of the effectiveness of the scheme 2/1 – 2 weeks of taking sunitinib at 50 mg per day, followed by a break for a week. This scheme allows to maintain the necessary concentration of the drug in the plasma. This, in its turn, reduces, the rate of side effects. In this article, a review of the literature on the efficacy of sunitinib using scheme 2/1 in patients with mRCC is given.
About the Authors
A. V. Byakhov
Moscow Clinical Scientific Center, Moscow
Russian Federation
MD, oncologist, Department of Clinical Oncology
Russian Federation
MD, oncologist, Department of Clinical Oncology
A. A. Khisamov
Moscow Clinical Scientific Center, Moscow
Russian Federation
MD, surgeon, Department of High-Tech Surgery
Russian Federation
MD, surgeon, Department of High-Tech Surgery
References
1. Hsieh J. J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y., Larkin J., Ficarra V. Renal cell carcinoma., Nat.Rev. Dis. Primers., 2017, Vol. 3, pp. 17009. doi: 10.1038/nrdp. 2017.9.
2. Ferlay J. et al. GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 1, 2013, GLOBOCAN http://globocan.iarc.fr (accessed on 4 Aug 2016).
3. Torre L.A. et al. Global cancer statistics, 2012, CA Cancer J. Clin., 2015, Vol. 65, pp. 87–108.
4. Global Burden of Disease Cancer Collaboration et al. The Global Burden of Cancer 2013, JAMA Oncol., 2015, Vol. 1, pp. 505–527.
5. Каприн А.Д., Старинский В.В., Петрова Г.В., Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Москва, 2017. 250 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality), Moscow, 2017, 250 p. (In Russ.)].
6. Motzer R. J., Hutson T. E., McCann L., Deen K., Choueiri T.K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib, N. Engl. J. Med., 2014, Vol. 370, pp. 1769–1770.
7. Schmid T.A., Gore M. E. Sunitinib in the treatment of metastatic renal cell carcinoma, Ther.Adv. Urol., 2016, Vol. 8, No. 6, pp. 348–371. Epub 2016 Aug 23.
8. Bracarda S., Negrier S., Casper J., Porta C., Schmidinger M., Larkin J., Gross Goupil M., Escudier B. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma, Expert. Rev. Anticancer Ther., 2017, Vol. 17, No. 3, pp. 227–233. doi: 10.1080/14737140.2017.1276830. Epub 2017 Jan 3. Review.
9. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., Raymond E. J. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosinekinase inhibitor, in patients with cancer, Clin. Oncol., 2006, Vol. 24, No. 1, pp. 25–35. Epub 2005 Nov 28.
10. Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S. T., Chen I., Huang X., Figlin R.A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J. Clin. Oncol., 2009, Vol. 27, No. 22, pp. 3584–90. doi: 10.1200/JCO. 2008.20.1293. Epub 2009 Jun 1.
11. Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 2007, Vol. 356, No. 2, pp. 115–24.
12. Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med., 2013, Vol. 369, No. 8, pp. 722–31. doi: 10.1056 / NEJMoa1303989.
13. Houk B. E., Bello C. L., Poland B., Rosen L.S., Demetri G.D., Motzer R. J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol., 2010, Vol. 66, No. 2, pp. 357–71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5.
14. Britten C.D., Kabbinavar F., Hecht J.R. et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period, Cancer Chemother, Pharmacol., 2008, Vol. 61, pp. 515–524.
15. Atkinson B. J., Kalra S., Wang X. et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules, J. Urol., 2014, Vol. 191, pp. 611–618.
16. Bjarnason G.A., Khalil B., Hudson J.M. et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature, Urol. Oncol., 2014, Vol. 32, pp. 480–487.
17. Bracarda S., Iacovelli R., Boni L. et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis, Ann. Oncol., 2015, Vol. 26, pp. 2107–2113.
18. Kondo T., Takagi T., Kobayashi H. et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-weekoff in patients with metastatic renal cell carcinoma – comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off, Jpn. J. Clin. Oncol., 2014, Vol. 44, pp. 270–277.
19. Najjar Y.G., Mittal K., Elson P. et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma, Eur. J. Cancer, 2014, Vol. 50, pp. 1084–1089.
20. Lee J.L., Kim M.K., Park I. et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial, Ann. Oncol., 2015, Vol. 26, No. 11, pp. 2300–2305.
21. Neri B., Vannini A., Brugia M. et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients, Int. J. Urol., 2013, Vol. 20, pp. 478–483.
22. Yoo C., Kim J. E., Lee J. L. et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction, Jpn. J. Clin. Oncol., 2010, Vol. 40, pp. 980–985.
23. Population pharmacokinetic/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor, Clin. Pharmacokinet., 2016, Vol. 55, pp. 1251–1269.
Review
For citations:
Byakhov A.V., Khisamov A.A. Possibilities of using alternative schemes of sunitinib therapy in patients with metastatic renal cell carcinoma. Malignant tumours. 2017;(2):90-93. (In Russ.) https://doi.org/10.18027/2224-5057-2017-2-90-93
Views:
1080
Email this article 